Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

Significant increases in biochemical response rates were observed in the overall population and in new patients. Treatment with CAM2029, an investigational once-monthly octreotide subcutaneous (SC) ...

Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (such as carcinoid tumors, vasoactive intestinal peptide tumors) that are ...

MUMBAI, Aug 17 (Reuters) - Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to make and market octreotide injection, the ...

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years Axitinib significantly ...

Socioeconomic disparities in access to and outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC). A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting ...